Addition of Xeloda to Herceptin and Docetaxel
 

San Antonio, Texas (ots/PRNewswire) - New data presented today atthe San Antonio Breast Cancer Symposium (SABCS) show that addingXeloda (capecitabine) to the current gold standard combination ofHerceptin (trastuzumab) and docetaxel allows patients with advancedHER2-positive breast cancer to live, on average 5 months longer untiltheir cancer starts to grow. The addition of capecitabine in thissetting represents an important advance in the treatment of anaggressive form of breast cancer and provides additional hope towomen with an otherwise poor prognosis

full article: http://www.juraforum.de/jura/news/ne.../210140/f/109/